SMMT
NASDAQSummit Therapeutics Inc.
Price$14.12-0.56 (-3.81%)
01:30 PM07:45 PM
News · 26 weeks45+150%
2025-12-142026-06-07
Mix2090d
- SEC Filings7(35%)
- Other5(25%)
- Analyst3(15%)
- Insider3(15%)
- Earnings2(10%)
Latest news
25 items- INSIDERCo-Chief Executive Officer Duggan Robert W bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)4 - Summit Therapeutics Inc. (0001599298) (Issuer)
- INSIDERCo-Chief Executive Officer Zanganeh Mahkam bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)4 - Summit Therapeutics Inc. (0001599298) (Issuer)
- INSIDERCOO and CFO Soni Manmeet Singh bought $722,250 worth of shares (50,000 units at $14.45), increasing direct ownership by 2% to 3,123,603 units (SEC Form 4)4 - Summit Therapeutics Inc. (0001599298) (Issuer)
- PRSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare ConferenceSummit Therapeutics Inc. (NASDAQ:SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentation will be available live through the company's website: www.smmttx.com. An archived version of the presentation will be available on the website following the presentation. About Summit Therapeutics Inc. Summit Therapeu
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- PRIvonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in ChinaIvonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Tolerable Safety Profile Consistent with Prior Clinical Trial Results Simultaneous Publication of Latest Ivonescimab HARMONi-6 Results in The Lancet Summit Conference Call to Be Held at 7:00 a.m. ET on Monday, June 1, 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducte
- PREncouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026Promising Data Further Support Continued Expansion of Ivonescimab Clinical Development in mCRC Overall Study Population Achieved ORR of 70.8% and DCR of 100.0%; Responses Consistent Across Ivonescimab Dose Levels Combined with Chemotherapy Acceptable and Manageable Safety Profile for Ivonescimab Regimen; No New Safety Signals Observed Summit Therapeutics Inc. (NASDAQ:SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were present
- ANALYSTSummit Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Summit Therapeutics from Buy to Neutral
- PRB7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters ClinicIssued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /CNW/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy tissue. It correlates with poor prognosis. On paper, it has every quality a drug developer wants. In practice, three B7-H3-targeting antibody-drug conjugates have entered the clinic, and none have yet been approved.[1] That is
- PRA Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in OncologyIssued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell engager just entered the clinic SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy ti
- SECSEC Form 10-Q filed by Summit Therapeutics Inc.10-Q - Summit Therapeutics Inc. (0001599298) (Filer)
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- PRSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China Update Conference Call to be Held on June 1, 2026 after ASCO Plenary Session HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Final PFS Data Expected in Second Half of 2026 with Interim OS Analyses Planned HARMONi-3 Non-Squamous Cohort of Global Phase III 1L NSCLC Study: PFS Data Expected in the First Half 2027 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2
- SECSEC Form DEFA14A filed by Summit Therapeutics Inc.DEFA14A - Summit Therapeutics Inc. (0001599298) (Filer)
- SECSEC Form DEF 14A filed by Summit Therapeutics Inc.DEF 14A - Summit Therapeutics Inc. (0001599298) (Filer)
- ANALYSTStifel initiated coverage on Summit Therapeutics with a new price targetStifel initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $45.00
- SECSEC Form PRE 14A filed by Summit Therapeutics Inc.PRE 14A - Summit Therapeutics Inc. (0001599298) (Filer)
- PRMultiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2026 European Lung Cancer Congress (ELCC 2026) in Copenhagen, Denmark. Three posters featuring updated ivonescimab data will be displayed on Friday, March 27 from 1:00 to 2:00 pm Central European Time. Data for HARMONi was generated and analyzed by Summit and for HARMONi-2 by our collaboration and licensing partner, Akeso Inc. (HKE
- ANALYSTSummit Therapeutics downgraded by Jefferies with a new price targetJefferies downgraded Summit Therapeutics from Buy to Hold and set a new price target of $15.00
- PRSummit Therapeutics to Present at Upcoming Investor ConferencesSummit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday, March 10, 2026 Investor meetings only Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026 Fireside chat 2:15pm ET The fireside chats will be available live on our website: www.
- SECSEC Form S-8 filed by Summit Therapeutics Inc.S-8 - Summit Therapeutics Inc. (0001599298) (Filer)
- SECSEC Form 10-K filed by Summit Therapeutics Inc.10-K - Summit Therapeutics Inc. (0001599298) (Filer)
- SECSummit Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Summit Therapeutics Inc. (0001599298) (Filer)
- PRSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in
SMMT FAQ
7 questionsWhat does Summit Therapeutics Inc. do?
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat...Where does SMMT stock trade?
Summit Therapeutics Inc. (SMMT) is listed on NASDAQ.What sector and industry is SMMT in?
Summit Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Summit Therapeutics Inc. go public?
Summit Therapeutics Inc. (SMMT) completed its IPO in 2015.What are analysts saying about SMMT?
Summit Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-05-22. Recent price targets range from $1300.00 to $4500.00.What companies are similar to SMMT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SMMT side-by-side with any of them on Quantisnow.How can I track SMMT on Quantisnow?
Quantisnow aggregates Summit Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SMMT to receive live email and push alerts on every new disclosure.